Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market ...

Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.

Nigeria’s fight against malaria may be entering a more dangerous phase as scientists reveal a new urban mosquito species and rising drug and insecticide resistance could reverse years of progress if ...

Precigen, Inc. ( PGEN) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 10:30 AM EST ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

SAN FRANCISCO – Alteogen, the most valuable biotech firm listed on Korea’s tech-heavy Kosdaq, is nearing another major ...

New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track ...

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...

After a busy first day featuring headlines from a who's who of leading biopharma companies, the J.P. | The J.P. Morgan ...

I think they’re just saying whatever they need to say right now to get approval,” Columbus resident Karlene Forbes told the ...

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...